肿瘤坏死因子相关凋亡诱导配体与赫赛汀联用对C-erbB2过表达的乳腺癌SKBR-3细胞株的影响  

The Effects of Tumor Necrosis Factor Related Apoptosis-inducing Ligand(TRAIL)Combined with Herceptin on Proliferation and Apoptosis of C-erbB2 Overexpression Breast Cancer SKBR-3 cell Lines

作　　者：张玉松[1] 傅晋祥[1] 周丽英[1] 周剑影[1] 郭晓葵[1] 

机构地区：[1]苏州大学附属第二医院肿瘤科,江苏苏州215004

出　　处：《苏州大学学报（医学版）》2007年第1期38-40,共3页Suzhou University Journal of Medical Science

摘　　要：目的探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)对人C-erbB2过表达的乳腺癌SKBR-3细胞株的作用及与赫赛汀(Herceptin)联用的可行性。方法SKBR-3细胞培养贴壁后,加入不同浓度的TRAIL、Herceptin、TRAIL联合Herceptin,MTT法检测抑制率,流式细胞术检测凋亡率。结果乳腺癌SKBR-3细胞对TRAIL不敏感,1μg/ml的TRAIL只能杀伤(5.54±1.12)%的细胞,TRAIL与Herceptin联用可增加对肿瘤细胞的抑制率,10、25μg/mlHer-ceptin与1μg/mlTRAIL联用的抑制率分别为(27.82±8.90)%、(36.89±7.60)%,与两药单用相比具有明显差异(均P<0.05)。10μg/mlHerceptin与1μg/mlTRAIL联用的凋亡率为(21.55±3.96)%,与两药单用相比具有明显差异(均P<0.05)。结论乳腺癌SKBR-3细胞株对TRAIL不敏感,但TRAIL与Herceptin联用可增加抗肿瘤作用,可能成为一种对C-erbB2过表达乳腺癌的新的治疗方法。Objective To investigate the anti-tumor effects of TRAIL and TRAIL combined with Herceptin in breast cancer cell lines SKBR-3. Methods TRAIL, Herceptin and TRAIL combined with Herceptin were added at different concentration at different scheduled SKBR-3 cells incubation time, MTT working solution was added and the inhibition was calculated. The rate of apoptosis was de flow cytometry. Results SKBR-3 ceils were not sensitive to TRAIL, the rate of killing was 1.12） % with TRAIL at concentration of 1 μg /ml. TRAIL combined with Herceptin upregulated tected by （5.54 ± the inhibition. The inhibition was （27.82 ± 8.90）%, （36. 89 ±7.60）% when 10, 25 μg/ml Herceptin combined with 1 μg /ml TRAIL was added, for which there was significant difference with that in the group using TRAIL or Herceptin alone. The rate of apoptosis in the group with 10 μg /ml Herceptin combined with 1 μg/ml TRAIL was （21.55 ±3.96）%, which also showed significant difference compared with that in the group using TRAIL with Herceptin alone. Conclusion TRAIL combined with Herceptin can effectively inhibit breast cell lines SKBR-3 even these ceils are resistant to TRAIL alone, which may be a new therapeutic method for treatment of C-erbB2 overexpression breast cancer.

关 键 词：乳腺癌 TRAIL 赫赛汀 

分 类 号：R737.905[医药卫生—肿瘤]